2026 Q1 -tulosraportti
Vain PDF
90 päivää sitten
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·18 t sittenSomeone asked about this news, I can't find you again so I'm putting it in here. Important changes in the pharmaceutical sector - the law on the stabilization of the statutory health insurance contribution rate comes into force on July 30, 2026. https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.htmlyes but I can't take credit for it, someone else found it, I just took the link and put it in here. By the way, I have found out that there is a word for the frustrations I have expressed earlier regarding Stenocare's management being silent as the grave. Because we find news about this and that, which possibly, can have an impact on the share price such as this one. Instead of the long explanations, I could just write that we are trading blind. sigh. Explanation for those of you who haven't heard of this concept either. In the financial world, it is called shareholders trading blind. In this context, it means that we as investors are effectively kept in the dark and forced to navigate without the necessary data. When management does not provide proactive, clear, and timely communication about the company's progress or decline. A company must ensure that all shareholders receive the same information at the same time, and if they don't, it is said that shareholders are trading blind. E.g., to spell it out. If a shareholder sells the share based on outdated information, because management has not told the market that an upward adjustment is coming, then this person may have missed out on a gain. Likewise, if a person buys a share based on outdated data, and the company subsequently issues a message about a downward adjustment that has come too late in relation to the disclosure obligation, then this person may also lose money. if something leaks out to unsuspecting people who trade on this inside knowledge, then it harms those who have not received this knowledge. I believe that we are fumbling in the dark, with this share, people are selling and buying on outdated data. It is solely the management's responsibility, because they are silent as the grave. https://www.finanstilsynet.dk/finansielle-temaer/kapitalmarked/markedsmisbrugsforordningen/intern-viden- ·20 t sittenStock status It is still sold out. Normally, I would refrain from writing anything when everything is status quo, but I do not believe it is a normal situation when, in the news that emerged earlier today, we can read that the subsidy for flower medicine has stopped as of last Friday, which is much earlier than initially announced; it was supposed to be from January 1, 2027. Furthermore, the article also stated that oil that is standardized (just like Weeco Astrum 10/10) is not affected by the quarantine. When Weeco Astrum 10/10 is not affected by the 6-month quarantine and the subsidy for flower medicine has stopped, I cannot help but speculate that pharmacies are sold out because there are bottlenecks with delivery, as it is still a stock item at the pharmacies that still have it in stock. To my knowledge, nothing has been released from Stenocare, so therefore it is speculation on my part, and I cannot say anything concrete; only the management from Stenocare can do that.
·20 t sittenAm I the only one who is starting to get impatient. My money could grow a lot faster with other stocks... What is your timeline?It's interesting that you write that you believe in it in the long run. The question is just whether what you call the long run is actually already playing out right now in Germany? If I am right that Stenocare already in Q2 has started making money in Germany, will you still think that you believe in it, in the long run? Or will you think differently about the stock? That is precisely what I mean by us trading blindly, and that management has big time neglected its disclosure obligation towards us in the stock market. When I read all the posts here at Stenocare, I think a common thread has started to emerge, that we are frustrated by the contrast we can see in the data coming from Germany, that it must have a positive impact on the sales of Weeco Astrum 10/10, but management is silent as the grave, and says nothing to us. You can see what they write on Finanstilsynet's website about the disclosure obligation, and there you will encounter the phrase, trading blindly and that it is far beyond the red line, for what the authority tolerates.- ·31.7.Stock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.You are right about that. Now we know that the subsidy for the flower medicine has been removed, from July 30. according to the article you dug up. As well as that Weeco Astrum 10/10 is NOT affected by the quarantine, because the oil is standardized. Now it makes sense why doctors out of the blue started prescribing Weeco Astrum 10/10, and why the oil is suddenly sold out, and it hasn't been restocked within 24 hours, which has been normal when it was sold out previously, as we saw mid-May. So it's the subsidy that has been removed, and not because Weeco Pharma has had an effective campaign, as I had guessed previously. I think it's strange that you dug up this news, and we haven't heard anything from PJ CFO and TS CEO yet. I think that when you have seen the news, and posted it here on Nordnet Social, they must also be aware of the above, after all, they are the ones with their hands in the dough.
- ·29.7.New update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
Vain PDF
90 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 t sittenSomeone asked about this news, I can't find you again so I'm putting it in here. Important changes in the pharmaceutical sector - the law on the stabilization of the statutory health insurance contribution rate comes into force on July 30, 2026. https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.htmlyes but I can't take credit for it, someone else found it, I just took the link and put it in here. By the way, I have found out that there is a word for the frustrations I have expressed earlier regarding Stenocare's management being silent as the grave. Because we find news about this and that, which possibly, can have an impact on the share price such as this one. Instead of the long explanations, I could just write that we are trading blind. sigh. Explanation for those of you who haven't heard of this concept either. In the financial world, it is called shareholders trading blind. In this context, it means that we as investors are effectively kept in the dark and forced to navigate without the necessary data. When management does not provide proactive, clear, and timely communication about the company's progress or decline. A company must ensure that all shareholders receive the same information at the same time, and if they don't, it is said that shareholders are trading blind. E.g., to spell it out. If a shareholder sells the share based on outdated information, because management has not told the market that an upward adjustment is coming, then this person may have missed out on a gain. Likewise, if a person buys a share based on outdated data, and the company subsequently issues a message about a downward adjustment that has come too late in relation to the disclosure obligation, then this person may also lose money. if something leaks out to unsuspecting people who trade on this inside knowledge, then it harms those who have not received this knowledge. I believe that we are fumbling in the dark, with this share, people are selling and buying on outdated data. It is solely the management's responsibility, because they are silent as the grave. https://www.finanstilsynet.dk/finansielle-temaer/kapitalmarked/markedsmisbrugsforordningen/intern-viden
- ·20 t sittenStock status It is still sold out. Normally, I would refrain from writing anything when everything is status quo, but I do not believe it is a normal situation when, in the news that emerged earlier today, we can read that the subsidy for flower medicine has stopped as of last Friday, which is much earlier than initially announced; it was supposed to be from January 1, 2027. Furthermore, the article also stated that oil that is standardized (just like Weeco Astrum 10/10) is not affected by the quarantine. When Weeco Astrum 10/10 is not affected by the 6-month quarantine and the subsidy for flower medicine has stopped, I cannot help but speculate that pharmacies are sold out because there are bottlenecks with delivery, as it is still a stock item at the pharmacies that still have it in stock. To my knowledge, nothing has been released from Stenocare, so therefore it is speculation on my part, and I cannot say anything concrete; only the management from Stenocare can do that.
- ·20 t sittenAm I the only one who is starting to get impatient. My money could grow a lot faster with other stocks... What is your timeline?It's interesting that you write that you believe in it in the long run. The question is just whether what you call the long run is actually already playing out right now in Germany? If I am right that Stenocare already in Q2 has started making money in Germany, will you still think that you believe in it, in the long run? Or will you think differently about the stock? That is precisely what I mean by us trading blindly, and that management has big time neglected its disclosure obligation towards us in the stock market. When I read all the posts here at Stenocare, I think a common thread has started to emerge, that we are frustrated by the contrast we can see in the data coming from Germany, that it must have a positive impact on the sales of Weeco Astrum 10/10, but management is silent as the grave, and says nothing to us. You can see what they write on Finanstilsynet's website about the disclosure obligation, and there you will encounter the phrase, trading blindly and that it is far beyond the red line, for what the authority tolerates.
- ·31.7.Stock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.You are right about that. Now we know that the subsidy for the flower medicine has been removed, from July 30. according to the article you dug up. As well as that Weeco Astrum 10/10 is NOT affected by the quarantine, because the oil is standardized. Now it makes sense why doctors out of the blue started prescribing Weeco Astrum 10/10, and why the oil is suddenly sold out, and it hasn't been restocked within 24 hours, which has been normal when it was sold out previously, as we saw mid-May. So it's the subsidy that has been removed, and not because Weeco Pharma has had an effective campaign, as I had guessed previously. I think it's strange that you dug up this news, and we haven't heard anything from PJ CFO and TS CEO yet. I think that when you have seen the news, and posted it here on Nordnet Social, they must also be aware of the above, after all, they are the ones with their hands in the dough.
- ·29.7.New update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
2026 Q1 -tulosraportti
Vain PDF
90 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 20.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 26.2. | ||
2025 Q3 -tulosraportti 22.10.2025 | ||
2025 Q2 -tulosraportti 21.8.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·18 t sittenSomeone asked about this news, I can't find you again so I'm putting it in here. Important changes in the pharmaceutical sector - the law on the stabilization of the statutory health insurance contribution rate comes into force on July 30, 2026. https://www.kvhh.net/de/praxis/verordnung/verordnung/wichtige-aenderungen-im-arzneimittelbereich-das-gkv-beitragssatzstabilisierungsgesetz-tritt-am-30-juli-2026-in-kraft.htmlyes but I can't take credit for it, someone else found it, I just took the link and put it in here. By the way, I have found out that there is a word for the frustrations I have expressed earlier regarding Stenocare's management being silent as the grave. Because we find news about this and that, which possibly, can have an impact on the share price such as this one. Instead of the long explanations, I could just write that we are trading blind. sigh. Explanation for those of you who haven't heard of this concept either. In the financial world, it is called shareholders trading blind. In this context, it means that we as investors are effectively kept in the dark and forced to navigate without the necessary data. When management does not provide proactive, clear, and timely communication about the company's progress or decline. A company must ensure that all shareholders receive the same information at the same time, and if they don't, it is said that shareholders are trading blind. E.g., to spell it out. If a shareholder sells the share based on outdated information, because management has not told the market that an upward adjustment is coming, then this person may have missed out on a gain. Likewise, if a person buys a share based on outdated data, and the company subsequently issues a message about a downward adjustment that has come too late in relation to the disclosure obligation, then this person may also lose money. if something leaks out to unsuspecting people who trade on this inside knowledge, then it harms those who have not received this knowledge. I believe that we are fumbling in the dark, with this share, people are selling and buying on outdated data. It is solely the management's responsibility, because they are silent as the grave. https://www.finanstilsynet.dk/finansielle-temaer/kapitalmarked/markedsmisbrugsforordningen/intern-viden
- ·20 t sittenStock status It is still sold out. Normally, I would refrain from writing anything when everything is status quo, but I do not believe it is a normal situation when, in the news that emerged earlier today, we can read that the subsidy for flower medicine has stopped as of last Friday, which is much earlier than initially announced; it was supposed to be from January 1, 2027. Furthermore, the article also stated that oil that is standardized (just like Weeco Astrum 10/10) is not affected by the quarantine. When Weeco Astrum 10/10 is not affected by the 6-month quarantine and the subsidy for flower medicine has stopped, I cannot help but speculate that pharmacies are sold out because there are bottlenecks with delivery, as it is still a stock item at the pharmacies that still have it in stock. To my knowledge, nothing has been released from Stenocare, so therefore it is speculation on my part, and I cannot say anything concrete; only the management from Stenocare can do that.
- ·20 t sittenAm I the only one who is starting to get impatient. My money could grow a lot faster with other stocks... What is your timeline?It's interesting that you write that you believe in it in the long run. The question is just whether what you call the long run is actually already playing out right now in Germany? If I am right that Stenocare already in Q2 has started making money in Germany, will you still think that you believe in it, in the long run? Or will you think differently about the stock? That is precisely what I mean by us trading blindly, and that management has big time neglected its disclosure obligation towards us in the stock market. When I read all the posts here at Stenocare, I think a common thread has started to emerge, that we are frustrated by the contrast we can see in the data coming from Germany, that it must have a positive impact on the sales of Weeco Astrum 10/10, but management is silent as the grave, and says nothing to us. You can see what they write on Finanstilsynet's website about the disclosure obligation, and there you will encounter the phrase, trading blindly and that it is far beyond the red line, for what the authority tolerates.
- ·31.7.Stock status. Medcanonestop was sold out at one pharmacy yesterday, today they are sold out at 3 pharmacies. Green Medical is sold out at 2 pharmacies Canngo is sold out at 2 pharmacies Flowzz was sold out at 1 pharmacy yesterday, today they are sold out at 2 pharmacies. Everything else is status Quo Good weekend to all.You are right about that. Now we know that the subsidy for the flower medicine has been removed, from July 30. according to the article you dug up. As well as that Weeco Astrum 10/10 is NOT affected by the quarantine, because the oil is standardized. Now it makes sense why doctors out of the blue started prescribing Weeco Astrum 10/10, and why the oil is suddenly sold out, and it hasn't been restocked within 24 hours, which has been normal when it was sold out previously, as we saw mid-May. So it's the subsidy that has been removed, and not because Weeco Pharma has had an effective campaign, as I had guessed previously. I think it's strange that you dug up this news, and we haven't heard anything from PJ CFO and TS CEO yet. I think that when you have seen the news, and posted it here on Nordnet Social, they must also be aware of the above, after all, they are the ones with their hands in the dough.
- ·29.7.New update on stock status. I just want to check if the different pharmacies have the oil in stock again. Last time it was sold out, it only took 2 hours, and then it was back in stock. This evening I have been able to ascertain that Weed.de is sold out at 3 pharmacies. I have double-checked that they have had 7 pharmacies, and I have counted many times that only 4 have the oil in stock. On July 20th, I wrote that they had gone from 3 to 7 pharmacies. Tell me, am I the only one who can see that Weeco Astrum 10/10 is being torn off the shelves in Germany???????? It has been sold out so many times now that I have lost track of the number of times. If the pharmacies that are sold out today do not have the oil in stock again tomorrow, we must expect. Delivery problems have arisen due to bottlenecks. I have been able to ascertain that Weeco Pharma has a warehouse in Düsseldorf, as they can rush-deliver the oil in 2 hours, and they also have a good network, since they have been able to deliver the oil in less than 24 hours the other times it has been sold out. I have to repeat myself. It is insane, and worrying, that there is total silence from Stenocares' management.That's an important point you're making. Firstly, Stenocare has no expenses in Germany regarding the sale of the oil; they have outsourced this to Weeco Pharma. Secondly. It doesn't matter if they have expenses or how much sales they have in Germany, as they should have issued the first company announcement because they started selling Weeco Astrum 10/10 already in Q2. It should have stated approximately: "According to financial law, we must send this announcement to the stock market. The sale of Weeco Astrum 10/10 has started selling in Germany here in Q2. We have stated that there will be no sales, but we have been able to ascertain that there are." The second is if there is an update to the financial statements, this must also be disclosed to the stock market as soon as they become aware of it. It is forbidden by law for them to only disclose it after they have become aware of an upward adjustment; this must be sent out the moment they can see that the financial statements need to be adjusted upwards. (the same applies to downward adjustments) If it turns out that I am right, which I am, then the management will be held accountable for the above negligence, based on the latest updated director's law. This will not affect the stock, because Stenocare makes money regardless of what happens to the management. I understand that my stock portfolios are under discussion, so let's close that once and for all. So it's not an advertisement for the shares I hold in my portfolio. As it is now, I have two stocks where I have invested the most. I own shares in Bioporto because I know they are on the verge of a global breakthrough with their product. The NGAL test. It's a medical stock, and with all medical equipment, it takes time, but it has slowly started; I have the shares I need to have. Stenocare. I started by buying a small portion of shares in Q4 2025. I have been watching this since they started cultivating cannabis flowers in Randers, but chose to enter in 2025. I started on May 13th by being on the heels of Weeco Pharma, and could see how their campaign for Weeco Astrum 10/10 succeeded, As soon as I, I was able to ascertain, and have shared with you here on Nordnet social, that they actually started selling the oil already in Q2, I began selling all other shares except Bioporto, even those at a loss, to buy Stenocare shares. All the new money I have been able to find, which has no deadline, I have used to buy Stenocare shares. I have 1 Hexicon share, purely out of laziness; it's easier to keep an eye on a stock when you own at least 1 share. Can you now understand how serious it is that PJ and TS have not informed the stock market, according to current legislation? Stock trading has almost come to a standstill, and that's because I have shared everything that has happened with Weeco Astrum 10/10 in Germany with you, and all of you and I, who have bought up and saved in our portfolio, have done so because we can see with our own eyes that there ARE sales in Germany. But they refuse to tell the stock market, and if PJ and TS had fulfilled their disclosure obligation, as required by law, this announcement would likely affect the stock price, and it would see a natural increase as management confirms it via a company announcement. We can see that there are many sales in Germany. It has nothing to do with my portfolio, but everything to do with management's behavior.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt